Syntaxin

Ipsen acquires Syntaxin

Monday, July 15, 2013

Global pharmaceutical company Ipsen has acquired Syntaxin, a U.K.-based private life sciences company specialized in botulinum toxin engineering. Ipsen will pay $36.4 million up front, as well as up to $169 million in development and commercial milestones.

[Read More]